Purpose of FIB-4 Score in Fatty Liver Disease
The FIB-4 score serves as a first-line, inexpensive screening tool to identify patients with fatty liver disease who are at risk for advanced liver fibrosis (stages F3-F4), thereby guiding decisions about further evaluation, specialist referral, and monitoring. 1
Primary Functions
Risk Stratification for Advanced Fibrosis
The FIB-4 score functions as the initial tier in a two-step risk stratification process for patients with nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD). It has demonstrated the best diagnostic accuracy for advanced fibrosis compared with other simple, nonproprietary fibrosis markers 1. Importantly, FIB-4 correlates not only with fibrosis stage but also with clinical outcomes in patients with NAFLD 1.
Clinical Decision-Making Based on Score Values
Low-risk patients (FIB-4 <1.3, or <2.0 if age >65 years): These individuals can reliably exclude advanced fibrosis with a negative predictive value ≥90%. They do not require immediate further evaluation but should undergo repeat FIB-4 testing in 2-3 years 1.
High-risk patients (FIB-4 >2.67): These patients warrant referral to hepatology for liver stiffness measurement or liver biopsy, as they have a 60-80% positive predictive value for advanced fibrosis 1.
Indeterminate-risk patients (FIB-4 1.3-2.67): This group, representing 30-40% of tested patients, requires second-tier testing with either elastography (transient elastography, shear wave elastography, or MR elastography) or proprietary serum biomarkers like Enhanced Liver Fibrosis (ELF) test 1.
Practical Advantages
The FIB-4 score is calculated using readily available laboratory values: age, AST, ALT, and platelet count, using the formula: age (years) × AST (U/L) / [platelet count (10⁹/L) × √ALT (U/L)] 2, 3. This makes it accessible in primary care settings without additional cost or specialized equipment 1.
Important Caveats and Limitations
Age-Related Performance Issues
FIB-4 performs poorly in patients younger than 35 years and has reduced specificity in those older than 65 years 3, 4. For elderly patients, the lower cutoff threshold of 2.0 (instead of 1.3) should be applied to avoid excessive false positives 1, 3.
Disease-Specific Limitations
In patients with type 2 diabetes, FIB-4 diagnostic accuracy may be suboptimal, with a significant proportion falling into the indeterminate range 1. The 2024 EASL-EASD-EASO guidelines note that FIB-4 as a single test may result in high numbers of false positives, especially in lower prevalence populations 3.
Sequential Testing Strategy
Recent evidence strongly supports that combining FIB-4 with a second noninvasive test (either imaging-based elastography or serum biomarkers like ELF) improves diagnostic accuracy and reduces the need for liver biopsy 4. A 2023 individual patient data meta-analysis demonstrated that sequential testing using FIB-4 followed by elastography can reduce liver biopsy needs from 33% to 19% 4.
Population-Based Screening Context
The FIB-4 score is specifically recommended for screening three high-risk populations: (A) patients with type 2 diabetes, (B) individuals with abdominal obesity plus ≥1 additional cardiometabolic risk factor, and (C) those with persistently elevated liver enzymes 3. Real-world implementation, such as the Camden and Islington NAFLD pathway, demonstrated a 5-fold increase in detection of advanced fibrosis and 3-fold increase in cirrhosis detection when using FIB-4-based screening 5.
Prognostic Value Beyond Fibrosis Staging
Beyond identifying current fibrosis stage, elevated FIB-4 values have been associated with all-cause and liver-related mortality in population-based studies 4. Recent research also suggests that changes in FIB-4 over time correlate with changes in steatohepatitis activity, potentially allowing monitoring of disease progression or treatment response 6.
The key clinical utility is that FIB-4 enables primary care providers to identify the minority of fatty liver patients (approximately 9-15% in at-risk populations) who have advanced fibrosis requiring specialist hepatology care, while safely reassuring the majority with low scores that they can be monitored in primary care 1.